Hyperglycaemia is associated with impaired pulsatile insulin secretion: Effect of basal insulin therapy

Diabetes, Obesity and Metabolism

Volumn 15, Issue 3, 2013, Pages 258-263

  Meier, J J ^a   Pennartz, C ^a   Schenker, N ^a   Menge, B A ^a   Schmidt, W E ^a   Heise, T ^b   Kapitza, C ^b   Veldhuis, J D ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b Profil Institute for Metabolic Research   (Germany)

^c MAYO CLINIC   (United States)

Author keywords

Insulin therapy; cell

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; INSULIN GLARGINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE RATE; TEST MEAL; THERAPY EFFECT;

EID: 84873845567     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12022     Document Type: Article

References (39)

1. Pørksen N, Nyholm B, Veldhuis JD, Butler PC, Schmitz O. In humans at least 75 % of insulin secretion arises from punctuated insulin secretory bursts. Am J Physiol Endocrinol Metab 1997; 273: E908-914.
2. Meier JJ, Butler PC. Insulin secretion. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 5 edn. Philadelphia, PA: Elsevier Saunders, 2005; 961-973.
3. Porksen N, Hollingdal M, Juhl C, Butler P, Veldhuis JD, Schmitz O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 2002; 51(Suppl. 1): S245-254.
4. Matveyenko AV, Liuwantara D, Gurlo T et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes 2012; 14: 2269-2279.
5. Matthews DR, Naylor BA, Jones RG, Ward GM, Turner RC. Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes 1983; 32: 617-621.
6. Schmitz O, Pedersen SB, Mengel A et al. Augmented effect of short-term pulsatile versus continuous insulin delivery on lipid metabolism but similar effect on whole-body glucose metabolism in obese subjects. Metabolism 1994; 43: 842-846.
7. Au S, Courtney CH, Ennis CN, Sheridan B, Atkinson AB, Bell PM. The effect of manipulation of basal pulsatile insulin on insulin action in type 2 diabetes. Diabet Med 2005; 22: 1064-1071.
8. Paolisso G, Scheen AJ, Giugliano D et al. Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. J Clin Endocrinol Metab 1991; 72: 607-615.
9. Hollingdal M, Juhl CB, Pincus SM et al. Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes 2000; 49: 1334-1340.
10. Laedtke T, Kjems L, Porksen N et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 2000; 279: E520-528.
11. Larsen MO, Gotfredsen CF, Wilken M, Carr RD, Porksen N, Rolin B. Loss of beta-cell mass leads to a reduction of pulse mass with normal periodicity, regularity and entrainment of pulsatile insulin secretion in Gottingen minipigs. Diabetologia 2003; 46: 195-202.
12. Matveyenko AV, Veldhuis JD, Butler PC. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 2006; 55: 2347-2356.
13. Matveyenko AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab 2008; 295: E832-841.
14. Pørksen N, Grofte B, Nyholm B et al. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion. Diabetes 1998; 47: 45-49.
15. Ritzel R, Schulte M, Porksen N et al. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 2001; 50: 776-784.
16. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11mM) glucose. J Clin Endocrinol Metab 2004; 89: 795-805.
17. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995; 18: 843-851.
18. Turner RC, McCarthy ST, Holman RR, Harris E. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976; 1: 1252-1254.
19. Pennartz C, Schenker N, Menge BA, Schmidt WE, Nauck MA, Meier JJ. Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 2011; 34: 2048-2053.
20. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34: 222-234.
21. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
22. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 2007; 33: 205-212.
23. Veldhuis JD, Johnson ML. Deconvolution analysis of hormone data. Methods Enzymol 1992; 210: 539-575.
24. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec: two-fold longer half-life and more consistent pharmacokinetic profile than insulin glargine (abstract). Diabetologia 2011; 54(Suppl. 1): 1046.
25. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D. Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1984; 74: 1318-1328.
26. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
27. Rorsman P, Eliasson L, Renstrom E, Gromada J, Barg S, Gopel S. The cell physiology of biphasic insulin secretion. News Physiol Sci 2000; 15: 72-77.
28. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004; 8: 42351-42354.
29. Ho E, Chen G, Bray TM. Supplementation of N-acetylcysteine inhibits NFkappaB activation and protects against alloxan-induced diabetes in CD-1 mice. FASEB J 1999; 13: 1845-1854.
30. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.
31. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.
32. Samols E, Stagner JI, Ewart RB, Marks V. The order of islet microvascular cellular perfusion is B-A-D in the perfused rat pancreas. J Clin Invest 1988; 82: 350-353.
33. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998; 19: 608-624.
34. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 2005; 54: 1649-1656.
35. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105.
36. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001; 44: 929-945.
37. Arnolds S, Dellweg S, Clair J et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33: 1509-1515.
38. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-112.
39. Nauck MA, Meier JJ. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells? Nat Rev Endocrinol 2011; 7: 193-195.